Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists

Nature Medicine

Volumn 13, Issue 6, 2007, Pages 725-729

  Buonpane, Rebecca A ^a,e   Churchill, Hywyn R O ^a   Moza, Beenu ^b   Sundberg, Eric J ^b   Peterson, Marnie L ^c   Schlievert, Patrick M ^d   Kranz, David M ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN FRAGMENT; RECEPTOR BLOCKING AGENT; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; RECEPTOR BINDING; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE ACTIVATION; YEAST;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DIRECTED MOLECULAR EVOLUTION; ENTEROTOXINS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SOLUBILITY;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; STAPHYLOCOCCUS AUREUS;

EID: 34250000045     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1584     Document Type: Article

References (26)

1. McCormick, J.K., Yarwood, J.M. & Schlievert, P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol. 55, 77-104 (2001).
2. Marrack, P. & Kappler, J. The staphylococcal entertoxins and their relatives. Science 248, 705-711 (1990).
3. Burnett, J.C., Henchal, E.A., Schmaljohn, A.L. & Bavari, S. The evolving field of biodefence: therapeutic developments and diagnostics. Nat. Rev. Drug Discov. 4, 281-297 (2005).
4. Crass, B.A. & Bergdoll, M.S. Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J. Clin. Microbiol. 23, 1138-1139 (1986).
5. Lee, V.T., Chang, A.H. & Chow, A.W. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS-associated Staphylococcus aureus isolates. J. Infect. Dis. 166, 911-915 (1992).
6. Andrews, M.M., Parent, E.M., Barry, M. & Parsonnet, J. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin. Infect. Dis. 32, 1470-1479 (2001).
7. Li, H., Llera, A., Malchiodi, E.L. & Mariuzza, R.A. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17, 435-466 (1999).
8. Kieke, M.C. et al. High affinity T cell receptors from yeast display libraries block T cell activation by superantigens. J. Mol. Biol. 307, 1305-1315 (2001).
9. Buonpane, R.A., Moza, B., Sundberg, E.J. & Kranz, D.M. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J. Mol. Biol. 353, 308-321 (2005).
10. Boder, E.T. & Wittrup, K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997).
11. Maynard, J.A. et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20, 597-601 (2002).
12. Razai, A. et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol. 351, 158-169 (2005).
13. Scobie, H.M. et al. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 192, 1047-1051 (2005).
14. Stone, R.L. & Schlievert, P.M. Evidence for the involvement of endotoxin in toxic shock syndrome. J. Infect. Dis. 155, 682-689 (1987).
15. Horn, D.L. et al. What are the microbial components implicated in the pathogenesis of sepsis? Report on a symposium. Clin. Infect. Dis. 31, 851-858 (2000).
16. Schlievert, P.M. Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect. Immun. 36, 123-128 (1982).
17. Holt, L.J., Herring, C., Jespers, L.S., Woolven, B.P. & Tomlinson, I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 21, 484-490 (2003).
18. Olafsen, T. et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65, 5907-5916 (2005).
19. Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immuno-conjugates. Nat. Biotechnol. 23, 1137-1146 (2005).
20. Hoogenboom, H.R. Selecting and screening recombinant antibody libraries. Nat. Biotechnol. 23, 1105-1116 (2005).
21. Holliger, P. & Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136 (2005).
22. Kaneko, Y., Nimmerjahn, F. & Ravetch, J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
23. Soo Hoo, W. & Kranz, D.M. Role of CD8 in staphylococcal enterotoxin B-mediated lysis by cytotoxic T lymphocytes. J. Immunol. 150, 4331-4337 (1993).
24. Reed, L.J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27, 493-497 (1938).
25. Parsonnet, J., Gillis, Z.A., Richter, A.G. & Pier, G.B. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect. Immun. 55, 1070-1076 (1987).
26. Roggiani, M., Stoehr, J.A., Leonard, B.A. & Schlievert, P.M. Analysis of toxicity of streptococcal pyrogenic exotoxin A mutants. Infect. Immun. 65, 2868-2875 (1997).